Source-grounded facts extracted from RECURSION PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
RECURSION PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-17 meeting.
“Proposal 3: The appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 was ratified, with the following votes cast: For Against Abstain 361,743,500 2,148,771 1,128,498”
RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve executive compensation at the 2026-06-17 meeting.
“Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: For Against Abstain Broker Non-Votes 206,171,008 30,893,147 1,280,852 126,675,762”
RECURSION PHARMACEUTICALS, INC. shareholders approved Election of Class II directors at the 2026-06-17 meeting.
“Proposal 1: The stockholders elected as Class II directors the two individuals listed below to serve until the Company’s 2029 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Najat Khan, Ph.D. 210,437,751 27,907,256 126,675,762 Franziska Michor, Ph.D. 208,124,737 30,220,270 126,675,762”
RECURSION PHARMACEUTICALS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
“today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its first quarter ended March 31, 2026.”
Christopher Gibson departed as Chair of the Board of Directors at RECURSION PHARMACEUTICALS, INC..
“On April 28, 2026, Christopher Gibson, Ph.D., Chair of the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to the Board as a Class II Director at the 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).”
RECURSION PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $11 million (approximately 20%).
“into the fourth quarter of 2027. These changes are expected to result in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $11 million in charges in connection with the workforce reduction, consisting of severance payments, employee benefits, and related costs, substantially all of which the Company expects to”
Dr. Namandjé Bumpus was appointed as Director at RECURSION PHARMACEUTICALS, INC..
“The Board appointed Dr. Bumpus as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as a member of the Nominating Committee of the Board, the Research and Development Committee of the Board, and the Technology Committee of the Board.”
Elaine Sun was appointed as Director at RECURSION PHARMACEUTICALS, INC..
“The Board appointed Ms. Sun as a Class III Director of the Board, with her initial term to extend until the 2027 Annual Meeting of Stockholders, and appointed her as the Chair of the Audit Committee of the Board and as a member of the Compensation Committee of the Board.”
RECURSION PHARMACEUTICALS, INC. completed an acquisition involving Exscientia plc for 0.7729 shares of Class A Common Stock per Exscientia Ordinary Share (closed 2024-11-20).
“(each a “Scheme Share”) was acquired by Recursion (or, at Recursion’s direction, by a nominee) from the holders of the Scheme Shares (each a “Scheme Shareholder”) in exchange for 0.7729 shares of Class A Common Stock (the “Company Class A Common Stock”) of the Company, par value of $0.00001 per share (the “Share Deliverable” and collectively the “Exchange”
Franziska Michor was appointed as Class II Director at RECURSION PHARMACEUTICALS, INC..
“the Board increased the number of members of the Board from 7 to 8 and appointed Franziska Michor, Ph.D., (“Dr. Michor”) as a Class II Director of the Board”
Ben Taylor was appointed as Chief Financial Officer of the Company and President of Recursion UK at RECURSION PHARMACEUTICALS, INC..
“Ben Taylor On November 20, 2024, the Board appointed Ben Taylor (“Mr. Taylor”), age 47, as Chief Financial Officer of the Company and President of Recursion UK, effective as of November 20, 2024.”
Michael Secora changed role as Chief Financial Officer at RECURSION PHARMACEUTICALS, INC..
“Michael Secora On November 20, 2024, the Company announced that Michael Secora (“Dr. Secora”), Chief Financial Officer of the Company, will be transitioning from his role as Chief Financial Officer, effective as of November 20, 2024.”
Terry-Ann Burrell resigned as Director and Chair of Audit Committee at RECURSION PHARMACEUTICALS, INC..
“On August 6, 2024, Terry-Ann Burrell informed the Company’s board of her decision to resign as a member of the Company’s board and Chair of its Audit Committee, effective August 12, 2024.”
Robert Hershberg changed role as Chair of the Board at RECURSION PHARMACEUTICALS, INC..
“the Board elected Robert Hershberg, M.D., Ph.D. as the Chair of the Board, effective at the 2024 Annual Meeting”
R. Martin Chavez departed as Chair of the Board at RECURSION PHARMACEUTICALS, INC..
“R. Martin Chavez, Ph.D., Chair of the Board and member of the Audit Committee of the Board, informed the Company that he will no longer stand for re-election to the Board as a Class III Director at the 2024 Annual Meeting of Stockholders”
RECURSION PHARMACEUTICALS, INC. reported financial results for first quarter ending March 31, 2024.
“On May 9, 2024, the Company issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2024.”
RECURSION PHARMACEUTICALS, INC. dismissed Ernst & Young LLP as its auditor.
“On May 7, 2024, the Audit Committee also dismissed Ernst & Young LLP ("EY") as our independent registered public accounting firm, beginning in the second fiscal quarter.”
RECURSION PHARMACEUTICALS, INC. engaged PricewaterhouseCoopers LLP as its auditor.
“on May 7, 2024, the Audit Committee approved the appointment of PricewaterhouseCoopers LLP ("PwC") as our independent registered public accounting firm, effective upon completion of PwC’s standard client acceptance process.”
Najat Khan was elected as Class II Director at RECURSION PHARMACEUTICALS, INC..
“increased the number of members of the Board from 8 to 9 and elected Najat Khan, Ph.D., as a Class II Director of the Board, effective April 16, 2024”
Najat Khan was appointed as Chief Research and Development Officer and Chief Commercial Officer at RECURSION PHARMACEUTICALS, INC..
“On April 16, 2024, the Company announced that Dr. Khan will be its Chief Research and Development Officer and Chief Commercial Officer, effective upon commencement of her employment with the Company.”
RECURSION PHARMACEUTICALS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2023”
Matthew Kinn was appointed as Chief Business Officer at RECURSION PHARMACEUTICALS, INC..
“Matthew Kinn, Senior Vice President, Business Development and Corporate Initiatives joined Recursion’s executive team and assumed all responsibilities previously held by Dr. Virani.”
Shafique Virani changed role as Senior Strategic Advisor at RECURSION PHARMACEUTICALS, INC..
“Dr. Shafique Virani, the Chief Business Officer of Recursion Pharmaceuticals, Inc. (the “Company” or “Recursion”) transitioned into a new role as a Senior Strategic Advisor.”
RECURSION PHARMACEUTICALS, INC.: Amended and restated Bylaws to enhance stockholder proposal procedures, adopt universal proxy rules, conform to DGCL, update director/officer provisions, and make other revisions (effective 2024-01-25).
“On January 25, 2024, the Board of Directors (the “Board”) of Recursion Pharmaceuticals, Inc. (the “Company”) amended and restated the Company’s Bylaws (the “Bylaws”), effective immediately.”
RECURSION PHARMACEUTICALS, INC. reported financial results for the third quarter ending September 30, 2023.
“On November 9, 2023, the Company issued a press release announcing its results of operations and financial condition for the third quarter September 30, 2023.”
RECURSION PHARMACEUTICALS, INC. amended Restated Bayer Agreement with Bayer AG valued at Amendment and restatement of the Original Research Collaboration and Option Agreement to re-align wi (effective 2023-11-08).
“On November 8, 2023, the parties amended and restated the Original Bayer Agreement (the “Restated Agreement”) to re-align the Original Agreement with Bayer’s strategic shift in focus to oncology, as further described below.”
RECURSION PHARMACEUTICALS, INC. entered into Tempus Master Agreement with Tempus Labs, Inc. valued at Initial license fee of $22.0 million; annual fees ranging from $22.0 million to $42.0 million; total (effective 2023-11-03).
“On November 3, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) and Tempus Labs, Inc. (“Tempus”) entered into a Master Agreement (the “Tempus Agreement”) pursuant to which Tempus may provide certain services and deliverables to Company and/or license certain data to Company.”
RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory vote on frequency of future shareholder advisory votes regarding named executive officer compensation at the 2023-06-16 meeting.
“Consistent with the recommendation of the Company’s Board of Directors (the “Board”), a majority of the votes at the Annual Meeting were cast in favor of conducting advisory Say-on-Pay votes on an annual basis.”
RECURSION PHARMACEUTICALS, INC. reported financial results for second quarter ending June 30, 2023.
“Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023.”
RECURSION PHARMACEUTICALS, INC. entered into Registration Rights Agreement with NVIDIA Corporation (effective 2023-07-11).
“In connection with the Private Placement, the Company and NVIDIA entered into a Registration Rights Agreement, dated July 11, 2023 (the “Registration Rights Agreement”), providing for the registration for resale of the Shares.”
RECURSION PHARMACEUTICALS, INC. entered into Purchase Agreement with NVIDIA Corporation valued at approximately $50 million (effective 2023-07-11).
“On July 11, 2023, Recursion Pharmaceuticals, Inc. (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with NVIDIA Corporation (“ NVIDIA ”). Pursuant to the Purchase Agreement, on July 11, 2023, the Company sold to NVIDIA an aggregate of 7,706,363 shares of the Company’s Class A common stock, par value $0.00001 per share (the “ Shares ”), at a purchase price of $6.488145 per Share in a private placement. The gross proceeds of the Private Placement were approximately $50 million”
RECURSION PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2023 at the 2023-06-16 meeting.
“Proposal 4: The appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2023 was ratified, with the following votes cast: For Against Abstain 210,585,521 71,005 197,818”
RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory vote on the frequency of the advisory vote on executive compensation at the 2023-06-16 meeting.
“Proposal 3: The advisory vote on the frequency of the advisory vote on executive compensation favored an annual vote, with the following votes cast: 1 Year 2 Years 3 Years Abstain Broker Non-Votes 180,126,697 17,141 598,617 146,188 29,965,701”
RECURSION PHARMACEUTICALS, INC. shareholders approved Advisory resolution to approve executive compensation at the 2023-06-16 meeting.
“Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast: For Against Abstain Broker Non-Votes 178,827,946 1,734,461 326,236 29,965,701”
RECURSION PHARMACEUTICALS, INC. shareholders approved Election of Christopher Gibson as Class II director at the 2023-06-16 meeting.
“Proposal 1: The stockholders elected as Class II directors the two individuals listed below to serve until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Terry-Ann Burrell, M.B.A. 163,422,186 17,466,457 29,965,701 Christopher Gibson, Ph.D. 169,410,560 11,478,083 29,965,701”
RECURSION PHARMACEUTICALS, INC. shareholders approved Election of Terry-Ann Burrell as Class II director at the 2023-06-16 meeting.
“Proposal 1: The stockholders elected as Class II directors the two individuals listed below to serve until the Company’s 2026 annual meeting of stockholders, or until their respective successors are duly elected and qualified. The voting results were as follows: Nominee For Withheld Broker Non-Votes Terry-Ann Burrell, M.B.A. 163,422,186 17,466,457 29,965,701 Christopher Gibson, Ph.D. 169,410,560 11,478,083 29,965,701”
Shafique Virani changed role as Interim Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..
“Shafique Virani, M.D., who has been serving in the role of Chief Corporate Development Officer and Interim Chief Medical Officer, will no longer hold the position of Interim Chief Medical Officer, effective June 1, 2023, but will continue serving in the role of Chief Corporate Development Officer.”
David Mauro was appointed as Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..
“On May 16, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) announced that it has appointed David Mauro, M.D., Ph.D., to the position of Chief Medical Officer, effective June 1, 2023.”
RECURSION PHARMACEUTICALS, INC. reported financial results for first quarter March 31, 2023.
“On May 8, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the first quarter March 31, 2023.”
RECURSION PHARMACEUTICALS, INC. reported financial results for the fourth quarter and fiscal year ended December 31, 2022.
“On February 27, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2022.”
RECURSION PHARMACEUTICALS, INC. reported third quarter September 30, 2022 results: revenue 13.2 million.
“Total revenue, consisting primarily of revenue from collaborative agreements, was $13.2 million for the third quarter of 2022, compared to $2.5 million for the third quarter of 2021.”
Shafique Virani was appointed as interim Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..
“Also, on June 7, 2022, the Company appointed Shafique Virani, MD FRCS, as interim CMO.”
Ramona Doyle departed as Chief Medical Officer at RECURSION PHARMACEUTICALS, INC..
“The employment of Ramona Doyle, MD as chief medical officer (“CMO”) of Recursion Pharmaceuticals, Inc. (the “Company”) ended on June 7, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.